Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL8765764 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29373533 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL6931932 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL5200899 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3908665 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | claimed |
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | claimed |
| EP-1795194-A2 | Use of an antagonist of CB1 receivers associated with a beta3-agonist for preparing medication to be used for treating appetence | Sanofi-Aventis (FR) | 2007-06-13 | — | — | EP | claimed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | claimed |
| EP-1745034-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | claimed |
| WO-2005077938-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-25 | — | — | WO | claimed |
| JP-3676383-B2 | — | — | 2005-07-27 | — | — | JP | claimed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | US | claimed |
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | claimed |
| EP-0489640-B1 | Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines | SANOFI SA (FR) | 1996-10-02 | — | — | EP | claimed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | claimed |
| US-5347037-A | (RR) and (RS stereoisomers of N-(7-ethoxycarbonylmethoxy-1,2,3,-tetrahydronaphth-2-yl)-2-(3-chlorophenyl)-2-hydroxyethanamine and their pharmaceutically acceptable salts | SANOFI (FR) | 1994-09-13 | — | — | US | claimed |
| US-5270341-A | Tetralin derivative | ELF SANOFI (FR) | 1993-12-14 | — | — | US | claimed |
| EP-0556880-A2 | Medical use for atypical beta-adrenoceptor agonists | GLAXO GROUP LIMITED (GB) | 1993-08-25 | — | — | EP | claimed |
| EP-0489640-A1 | Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines | SANOFI (FR) | 1992-06-10 | — | — | EP | claimed |
| EP-0403360-A2 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI (FR) | 1990-12-19 | — | — | EP | claimed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | claimed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, ADRB3 | ADRB3 3/4885ADRB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.